Forward Pharma A/S (FWP) 31.77 $FWP
Seeking Alpha's Biotech Weekly: Celgene Check-Up, Is Gilead The New Apple?, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 17, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors geared up for earnings season, highlighted several...
SGYP: 4.01 (-0.06), BIIB: 423.57 (+1.46), ARWR: 6.88 (+0.14), AMGN: 169.10 (+0.64), MYL: 72.40 (-1.67), BMY: 66.60 (-0.21), CNCE: 14.83 (+0.26), CELG: 115.54 (+0.72), ATNM: 3.01 (-0.07), PFS: 18.65 (+0.06), NVIV: 13.76 (-0.19), GILD: 104.18 (-1.02), FWP: 31.77 (-0.66), GWPH: 113.04 (-0.05), IBM: 165.36 (+1.10), BAX: 70.38 (+0.33), AZN: 73.35 (+0.65), TEVA: 63.01 (-1.15)
Biogen Reports New Data from Acute Optic Neuritis Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 15, 5:10PM CDT
Biogen (BIIB) announced positive new data from the phase II RENEW study on anti-LINGO-1 for acute optic neuritis.
BIIB: 423.57 (+1.46), FWP: 31.77 (-0.66), AMGN: 169.10 (+0.64), AFFX: 12.57 (-0.13)
U.S. Patent Office declares an interference between Forward Pharma and Biogen over dimethyl fumarate
Seeking Alpha - at Seeking Alpha - Tue Apr 14, 11:05AM CDT
BIIB: 423.57 (+1.46), FWP: 31.77 (-0.66)
U.S. Patent Office Declares an Interference Between Forward Pharma and Biogen Regarding the Treatment of Multiple Sclerosis With 480 mg Daily Dose of DMF, the Active Ingredient in Tecfidera(R)
GlobeNewswire - Tue Apr 14, 10:22AM CDT
Forward Pharma A/S (Nasdaq:FWP) (the "Company"
announced today that an interference was declared by the Patent Trial and Appeal Board (PTAB) on April 13, 2015 between the Company's patent application 11/576,871 (the "'871 patent application" and Biogen's issued patent 8,399,514 (the "'514 patent". The PTAB designated the Company as the "Senior Party" in the interference based on the Company's earlier patent application filing date.
FWP: 31.77 (-0.66)
Forward Pharma Pre-IPO Investors Voluntarily Agree to Extend Lock-Up
GlobeNewswire - Thu Apr 09, 4:32PM CDT
Forward Pharma A/S (Nasdaq:FWP) (the "Company" or "Forward" announced today an agreement among all of its pre-IPO shareholders to voluntarily lock-up their shares for an additional 365 days beyond the expiration of the original IPO lock-up. These shareholders collectively account for over 75% of the Company's shares outstanding. The original lock-up agreement with the IPO underwriters expires on April 12, 2015. The new lock-up expires on April 12, 2016.
FWP: 31.77 (-0.66), NBD: 21.57 (-0.13)
Forward Pharma net loss improves in Q4
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 8:37AM CDT
FWP: 31.77 (-0.66)
Forward Pharma EPS of -$1.01
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 5:38AM CDT
FWP: 31.77 (-0.66)
Forward Pharma Reports Fourth Quarter and Year End 2014 Financial and Operational Results
GlobeNewswire - Wed Mar 25, 5:30AM CDT
Forward Pharma A/S (Nasdaq:FWP), today reported financial results for the fourth quarter and year ended December 31, 2014. Net loss for the fourth quarter and year ended December 31, 2014 was $2.0 million and $19.0 million, respectively. Loss per share for the fourth quarter and year ended December 31, 2014 was $1.01 and $1.79, respectively, after accounting for a non-cash preferential distribution of approximately $42.7 million. As of December 31, 2014, Forward had $223.5 million in cash, cash equivalents and marketable securities, with no debt outstanding.
FWP: 31.77 (-0.66)
4 Stocks Breaking Out on Unusual Volume: Forward Pharma and More
at The Street - Mon Mar 16, 11:36AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
ZUMZ: 33.98 (-0.33), KNDI: 12.22 (+0.11), FWP: 31.77 (-0.66), BRSS: 15.30 (+0.25)
Forward Pharma CFO to Present at the Future Leaders Conference on March 20th
GlobeNewswire - Mon Mar 16, 7:30AM CDT
Forward Pharma A/S (Nasdaq:FWP), a biopharmaceutical company working to advance a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis and other immune disorders such as psoriasis, today announced that Joel Sendek, Forward Pharma's Chief Financial Officer, will present at the following conference:
FWP: 31.77 (-0.66)
Seeking Baupost: The Hidden Holdings - Part III
Matthew Finston - at Seeking Alpha - Sat Feb 28, 5:35AM CST
OCN: 7.68 (+0.14), PRTK: 28.96 (+0.61), KOS: 8.48 (-0.02), KIN: 7.45 (+0.25), VSAT: 62.14 (-0.45), BXE: 3.13 (unch), EBAY: 56.75 (+0.33), SEMI: 24.23 (+0.04), TBPH: 18.41 (+0.18), THRX: 17.08 (+0.45), VRTV: 41.62 (+1.04), IMOS: 24.00 (+0.47), GLNG: 35.48 (+0.87), ELOS: 12.19 (-0.10), MU: 29.50 (+0.95), AR: 41.95 (+0.57), NCQ: 0.61 (unch), PBF: 29.60 (+0.40), LNG: 78.61 (+1.61), ATRA: 63.79 (+7.64), KERX: 11.52 (-0.15), NG: 3.56 (-0.07), AOI: 1.46 (+0.08), FWP: 31.77 (-0.66), ALDW: 19.87 (+0.32)
Seeking Baupost: The Himalayan Yeti Frightens
Matthew Finston - at Seeking Alpha - Tue Feb 24, 7:49AM CST
ELOS: 12.19 (-0.10), MU: 29.50 (+0.95), AR: 41.95 (+0.57), PBF: 29.60 (+0.40), OCN: 7.68 (+0.14), NCQ: 0.61 (unch), LNG: 78.61 (+1.61), ATRA: 63.79 (+7.64), PRTK: 28.96 (+0.61), KOS: 8.48 (-0.02), KIN: 7.45 (+0.25), VSAT: 62.14 (-0.45), KERX: 11.52 (-0.15), NG: 3.56 (-0.07), BXE: 3.13 (unch), AOI: 1.46 (+0.08), EBAY: 56.75 (+0.33), ALDW: 19.87 (+0.32), FWP: 31.77 (-0.66), SEMI: 24.23 (+0.04), VRTV: 41.62 (+1.04), THRX: 17.08 (+0.45), TBPH: 18.41 (+0.18), IMOS: 24.00 (+0.47)
Tracking Seth Klarman's Baupost Group Holdings - Q4 2014 Update
John Vincent - at Seeking Alpha - Sun Feb 15, 1:07AM CST
OCN: 7.68 (+0.14), PRTK: 28.96 (+0.61), KOS: 8.48 (-0.02), KIN: 7.45 (+0.25), VSAT: 62.14 (-0.45), BXE: 3.13 (unch), EBAY: 56.75 (+0.33), SEMI: 24.23 (+0.04), VRTV: 41.62 (+1.04), THRX: 17.08 (+0.45), TBPH: 18.41 (+0.18), IMOS: 24.00 (+0.47), ELOS: 12.19 (-0.10), MU: 29.50 (+0.95), AR: 41.95 (+0.57), NCQ: 0.61 (unch), PBF: 29.60 (+0.40), LNG: 78.61 (+1.61), ATRA: 63.79 (+7.64), KERX: 11.52 (-0.15), NG: 3.56 (-0.07), AOI: 1.46 (+0.08), QRVO: 74.48 (+0.41), FWP: 31.77 (-0.66), ALDW: 19.87 (+0.32), SUNE: 27.27 (+0.56), AIG: 56.58 (-0.06)
Forward Pharma CFO to Present at Two Upcoming Conferences in February
GlobeNewswire - Thu Feb 05, 10:00AM CST
Forward Pharma A/S (Nasdaq:FWP), a biopharmaceutical company working to advance a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis and other immune disorders such as psoriasis, today announced that Joel Sendek, Forward Pharma's Chief Financial Officer, will present at the following conferences:
FWP: 31.77 (-0.66)
XenoPort Prepping For Key Data In 2015
Stephen Simpson, CFA - at Seeking Alpha - Wed Jan 14, 4:59PM CST
BIIB: 423.57 (+1.46), FWP: 31.77 (-0.66), ALKS: 62.60 (-0.24), XNPT: 7.42 (+0.12)
The New Baupost Biotech Picks
Matthew Finston - at Seeking Alpha - Mon Dec 15, 8:53AM CST
BIIB: 423.57 (+1.46), FWP: 31.77 (-0.66), MRK: 57.69 (+0.03), AVEO: 2.04 (+0.12), ATRA: 63.79 (+7.64), THRX: 17.08 (+0.45), TBPH: 18.41 (+0.18), PRTK: 28.96 (+0.61), KIN: 7.45 (+0.25), KERX: 11.52 (-0.15)
Forward Pharma A/S Prices Initial Public Offering of ADSs
PR Newswire Europe - Wed Nov 26, 1:51PM CST
Forward Pharma A/S, a biopharmaceutical company working to advance a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis and other immune disorders such as psoriasis, today announced the pricing of its initial public offering of 10,500,000 American Depositary Shares ("ADSs", representing the Company's ordinary shares, at a price to the public of $21.00 per ADS. The ADSs are expected to begin trading today on the NASDAQ Global Select Market under the ticker symbol "FWP". The Company has granted the underwriters a 30-day option to purchase up to an additional 1,575,000 ADSs to cover over-allotments, if any.
FWP: 31.77 (-0.66)
Forward Pharma A/S Announces Proposed Initial Public Offering of ADSs
PR Newswire Europe - Wed Nov 26, 8:41AM CST
Forward Pharma A/S, a biopharmaceutical company working to advance a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis and other immune disorders such as psoriasis, today announced it has commenced an underwritten initial public offering of its American Depositary Shares ("ADSs". The Company currently expects the initial public offering price to be between $20.00 and $22.00 and the ADSs are expected to trade on the NASDAQ under the ticker symbol "FWP."
FWP: 31.77 (-0.66)
Forward Pharma Receives Issue Notification for Erosion Matrix Patent in the U.S.
GlobeNewswire - Mon Nov 24, 7:30AM CST
Forward Pharma A/S (Nasdaq:FWP) ("the Company" announced today that the Company received an issue notification from the United States Patent and Trademark Office (USPTO) regarding its patent application 13/143,498 covering its erosion matrix formulation of dimethyl fumarate (DMF). The application is entitled "Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix". The USPTO projects that the application will issue with the patent number 8,906,420 on December 9, 2014. The patent will expire in January 2030.
FWP: 31.77 (-0.66)
Forward Pharma Sues Biogen Idec Over Tecfidera(R) Sales in Germany
GlobeNewswire - Tue Nov 18, 7:41AM CST
Forward Pharma A/S (Nasdaq:FWP) announced today that it has filed a lawsuit against Biogen Idec GmbH, Biogen Idec International GmbH and Biogen Idec Ltd. in the Regional Court in Dusseldorf, alleging infringement of its German utility model DE 20 2005 022 112 due to Biogen Idec's marketing of Tecfidera(R) in Germany. With this lawsuit Forward Pharma ("the Company" does not seek to stop sales of Tecfidera(R) to MS patients, but rather seeks damages for what the Company believes are Biogen Idec's unlawful sales of Tecfidera(R) in Germany.
BIIB: 423.57 (+1.46), FWP: 31.77 (-0.66)
Seeking Alpha's Biotech Weekly: Celgene Check-Up, Is Gilead The New Apple?, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 17, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors geared up for earnings season, highlighted several...
SGYP: 4.01 (-0.06), BIIB: 423.57 (+1.46), ARWR: 6.88 (+0.14), AMGN: 169.10 (+0.64), MYL: 72.40 (-1.67), BMY: 66.60 (-0.21), CNCE: 14.83 (+0.26), CELG: 115.54 (+0.72), ATNM: 3.01 (-0.07), PFS: 18.65 (+0.06), NVIV: 13.76 (-0.19), GILD: 104.18 (-1.02), FWP: 31.77 (-0.66), GWPH: 113.04 (-0.05), IBM: 165.36 (+1.10), BAX: 70.38 (+0.33), AZN: 73.35 (+0.65), TEVA: 63.01 (-1.15)
Biogen Reports New Data from Acute Optic Neuritis Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 15, 5:10PM CDT
Biogen (BIIB) announced positive new data from the phase II RENEW study on anti-LINGO-1 for acute optic neuritis.
BIIB: 423.57 (+1.46), FWP: 31.77 (-0.66), AMGN: 169.10 (+0.64), AFFX: 12.57 (-0.13)
U.S. Patent Office declares an interference between Forward Pharma and Biogen over dimethyl fumarate
Seeking Alpha - at Seeking Alpha - Tue Apr 14, 11:05AM CDT
BIIB: 423.57 (+1.46), FWP: 31.77 (-0.66)
U.S. Patent Office Declares an Interference Between Forward Pharma and Biogen Regarding the Treatment of Multiple Sclerosis With 480 mg Daily Dose of DMF, the Active Ingredient in Tecfidera(R)
GlobeNewswire - Tue Apr 14, 10:22AM CDT
Forward Pharma A/S (Nasdaq:FWP) (the "Company"
announced today that an interference was declared by the Patent Trial and Appeal Board (PTAB) on April 13, 2015 between the Company's patent application 11/576,871 (the "'871 patent application" and Biogen's issued patent 8,399,514 (the "'514 patent". The PTAB designated the Company as the "Senior Party" in the interference based on the Company's earlier patent application filing date. FWP: 31.77 (-0.66)
Forward Pharma Pre-IPO Investors Voluntarily Agree to Extend Lock-Up
GlobeNewswire - Thu Apr 09, 4:32PM CDT
Forward Pharma A/S (Nasdaq:FWP) (the "Company" or "Forward"
announced today an agreement among all of its pre-IPO shareholders to voluntarily lock-up their shares for an additional 365 days beyond the expiration of the original IPO lock-up. These shareholders collectively account for over 75% of the Company's shares outstanding. The original lock-up agreement with the IPO underwriters expires on April 12, 2015. The new lock-up expires on April 12, 2016. FWP: 31.77 (-0.66), NBD: 21.57 (-0.13)
Forward Pharma net loss improves in Q4
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 8:37AM CDT
FWP: 31.77 (-0.66)
Forward Pharma EPS of -$1.01
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 5:38AM CDT
FWP: 31.77 (-0.66)
Forward Pharma Reports Fourth Quarter and Year End 2014 Financial and Operational Results
GlobeNewswire - Wed Mar 25, 5:30AM CDT
Forward Pharma A/S (Nasdaq:FWP), today reported financial results for the fourth quarter and year ended December 31, 2014. Net loss for the fourth quarter and year ended December 31, 2014 was $2.0 million and $19.0 million, respectively. Loss per share for the fourth quarter and year ended December 31, 2014 was $1.01 and $1.79, respectively, after accounting for a non-cash preferential distribution of approximately $42.7 million. As of December 31, 2014, Forward had $223.5 million in cash, cash equivalents and marketable securities, with no debt outstanding.
FWP: 31.77 (-0.66)
4 Stocks Breaking Out on Unusual Volume: Forward Pharma and More
at The Street - Mon Mar 16, 11:36AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
ZUMZ: 33.98 (-0.33), KNDI: 12.22 (+0.11), FWP: 31.77 (-0.66), BRSS: 15.30 (+0.25)
Forward Pharma CFO to Present at the Future Leaders Conference on March 20th
GlobeNewswire - Mon Mar 16, 7:30AM CDT
Forward Pharma A/S (Nasdaq:FWP), a biopharmaceutical company working to advance a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis and other immune disorders such as psoriasis, today announced that Joel Sendek, Forward Pharma's Chief Financial Officer, will present at the following conference:
FWP: 31.77 (-0.66)
Seeking Baupost: The Hidden Holdings - Part III
Matthew Finston - at Seeking Alpha - Sat Feb 28, 5:35AM CST
OCN: 7.68 (+0.14), PRTK: 28.96 (+0.61), KOS: 8.48 (-0.02), KIN: 7.45 (+0.25), VSAT: 62.14 (-0.45), BXE: 3.13 (unch), EBAY: 56.75 (+0.33), SEMI: 24.23 (+0.04), TBPH: 18.41 (+0.18), THRX: 17.08 (+0.45), VRTV: 41.62 (+1.04), IMOS: 24.00 (+0.47), GLNG: 35.48 (+0.87), ELOS: 12.19 (-0.10), MU: 29.50 (+0.95), AR: 41.95 (+0.57), NCQ: 0.61 (unch), PBF: 29.60 (+0.40), LNG: 78.61 (+1.61), ATRA: 63.79 (+7.64), KERX: 11.52 (-0.15), NG: 3.56 (-0.07), AOI: 1.46 (+0.08), FWP: 31.77 (-0.66), ALDW: 19.87 (+0.32)
Seeking Baupost: The Himalayan Yeti Frightens
Matthew Finston - at Seeking Alpha - Tue Feb 24, 7:49AM CST
ELOS: 12.19 (-0.10), MU: 29.50 (+0.95), AR: 41.95 (+0.57), PBF: 29.60 (+0.40), OCN: 7.68 (+0.14), NCQ: 0.61 (unch), LNG: 78.61 (+1.61), ATRA: 63.79 (+7.64), PRTK: 28.96 (+0.61), KOS: 8.48 (-0.02), KIN: 7.45 (+0.25), VSAT: 62.14 (-0.45), KERX: 11.52 (-0.15), NG: 3.56 (-0.07), BXE: 3.13 (unch), AOI: 1.46 (+0.08), EBAY: 56.75 (+0.33), ALDW: 19.87 (+0.32), FWP: 31.77 (-0.66), SEMI: 24.23 (+0.04), VRTV: 41.62 (+1.04), THRX: 17.08 (+0.45), TBPH: 18.41 (+0.18), IMOS: 24.00 (+0.47)
Tracking Seth Klarman's Baupost Group Holdings - Q4 2014 Update
John Vincent - at Seeking Alpha - Sun Feb 15, 1:07AM CST
OCN: 7.68 (+0.14), PRTK: 28.96 (+0.61), KOS: 8.48 (-0.02), KIN: 7.45 (+0.25), VSAT: 62.14 (-0.45), BXE: 3.13 (unch), EBAY: 56.75 (+0.33), SEMI: 24.23 (+0.04), VRTV: 41.62 (+1.04), THRX: 17.08 (+0.45), TBPH: 18.41 (+0.18), IMOS: 24.00 (+0.47), ELOS: 12.19 (-0.10), MU: 29.50 (+0.95), AR: 41.95 (+0.57), NCQ: 0.61 (unch), PBF: 29.60 (+0.40), LNG: 78.61 (+1.61), ATRA: 63.79 (+7.64), KERX: 11.52 (-0.15), NG: 3.56 (-0.07), AOI: 1.46 (+0.08), QRVO: 74.48 (+0.41), FWP: 31.77 (-0.66), ALDW: 19.87 (+0.32), SUNE: 27.27 (+0.56), AIG: 56.58 (-0.06)
Forward Pharma CFO to Present at Two Upcoming Conferences in February
GlobeNewswire - Thu Feb 05, 10:00AM CST
Forward Pharma A/S (Nasdaq:FWP), a biopharmaceutical company working to advance a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis and other immune disorders such as psoriasis, today announced that Joel Sendek, Forward Pharma's Chief Financial Officer, will present at the following conferences:
FWP: 31.77 (-0.66)
XenoPort Prepping For Key Data In 2015
Stephen Simpson, CFA - at Seeking Alpha - Wed Jan 14, 4:59PM CST
BIIB: 423.57 (+1.46), FWP: 31.77 (-0.66), ALKS: 62.60 (-0.24), XNPT: 7.42 (+0.12)
The New Baupost Biotech Picks
Matthew Finston - at Seeking Alpha - Mon Dec 15, 8:53AM CST
BIIB: 423.57 (+1.46), FWP: 31.77 (-0.66), MRK: 57.69 (+0.03), AVEO: 2.04 (+0.12), ATRA: 63.79 (+7.64), THRX: 17.08 (+0.45), TBPH: 18.41 (+0.18), PRTK: 28.96 (+0.61), KIN: 7.45 (+0.25), KERX: 11.52 (-0.15)
Forward Pharma A/S Prices Initial Public Offering of ADSs
PR Newswire Europe - Wed Nov 26, 1:51PM CST
Forward Pharma A/S, a biopharmaceutical company working to advance a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis and other immune disorders such as psoriasis, today announced the pricing of its initial public offering of 10,500,000 American Depositary Shares ("ADSs"
, representing the Company's ordinary shares, at a price to the public of $21.00 per ADS. The ADSs are expected to begin trading today on the NASDAQ Global Select Market under the ticker symbol "FWP". The Company has granted the underwriters a 30-day option to purchase up to an additional 1,575,000 ADSs to cover over-allotments, if any. FWP: 31.77 (-0.66)
Forward Pharma A/S Announces Proposed Initial Public Offering of ADSs
PR Newswire Europe - Wed Nov 26, 8:41AM CST
Forward Pharma A/S, a biopharmaceutical company working to advance a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis and other immune disorders such as psoriasis, today announced it has commenced an underwritten initial public offering of its American Depositary Shares ("ADSs"
. The Company currently expects the initial public offering price to be between $20.00 and $22.00 and the ADSs are expected to trade on the NASDAQ under the ticker symbol "FWP." FWP: 31.77 (-0.66)
Forward Pharma Receives Issue Notification for Erosion Matrix Patent in the U.S.
GlobeNewswire - Mon Nov 24, 7:30AM CST
Forward Pharma A/S (Nasdaq:FWP) ("the Company"
announced today that the Company received an issue notification from the United States Patent and Trademark Office (USPTO) regarding its patent application 13/143,498 covering its erosion matrix formulation of dimethyl fumarate (DMF). The application is entitled "Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix". The USPTO projects that the application will issue with the patent number 8,906,420 on December 9, 2014. The patent will expire in January 2030. FWP: 31.77 (-0.66)
Forward Pharma Sues Biogen Idec Over Tecfidera(R) Sales in Germany
GlobeNewswire - Tue Nov 18, 7:41AM CST
Forward Pharma A/S (Nasdaq:FWP) announced today that it has filed a lawsuit against Biogen Idec GmbH, Biogen Idec International GmbH and Biogen Idec Ltd. in the Regional Court in Dusseldorf, alleging infringement of its German utility model DE 20 2005 022 112 due to Biogen Idec's marketing of Tecfidera(R) in Germany. With this lawsuit Forward Pharma ("the Company"
does not seek to stop sales of Tecfidera(R) to MS patients, but rather seeks damages for what the Company believes are Biogen Idec's unlawful sales of Tecfidera(R) in Germany. BIIB: 423.57 (+1.46), FWP: 31.77 (-0.66)
